EW Edwards Lifesciences Corporation

Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...

Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...

Edwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE

The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.

Despite lagging behind the Dow over the past 12 months, Edwards Lifesciences continues to receive a highly bullish outlook from Wall Street analysts.

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.

An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The amount KKR agreed to pay to settle a case with the Justice Department alleging that the private-equity giant withheld and altered documents in premerger filings. The previous record, a $12 million penalty, was collectively held by Edwards Lifesciences and Genesis MedTech. The DOJ said late yesterday that KKR failed to make complete and accurate filings for at least 16 deals in 2021 and 2022.

Medtronic's Q1 results may reflect strong growth across Cardiovascular, Neuroscience and Diabetes, but earnings beat signals remain mixed.

STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.

Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.

Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.

Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Investors need to pay close attention to EW stock based on the movements in the options market lately.

Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

On July 23, Edwards Lifesciences Corporation (NYSE:EW) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency basis), surpassing Wall Street expectations of $1.70 billion. Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a […]

Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...

SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls

Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

Moby summary of Edwards Lifesciences Corporation's Q2 2026 earnings call

An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with moderate disease are expected to help the company maintain its momentum.

Edwards Lifesciences Corp (EW) reports a robust 12.5% sales increase, driven by innovation and strategic growth across key segments.

Edwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products. Chief Executive Officer Bernard Zovighian said the

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.

Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line expectations.

EW heads into Q2 earnings results with estimates calling for double-digit revenue growth as TAVR, TMTT and Surgical heart businesses remain in focus.

The FTC secured the penalty after a court ruled that Edwards failed to comply with antitrust law requirements when it acquired JC Medical in 2024.

(Bloomberg) -- The Federal Trade Commission urged a judge to block Henkel AG’s $725 million purchase of part of Pittsburgh Paint Co., saying the deal would harm competition in the liquid-adhesive market by combining two of its biggest players.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Restarts Iran Blockade as US Plans 20% Hormuz ChargeTrump Embraces Australian Retirement System Backed by Larry FinkOpenAI Engineer’s ‘LOL’ Moment Set Stage for Legal Fig

The artificial heart valve maker will settle allegations it deliberately structured its deal to acquire JC Medical to sidestep a Hart-Scott-Rodino review.